摘要
目的评价羟自由基清除剂-依达拉奉注射液治疗急性脑梗死的有效性和安全性。方法将82例急性脑梗死患者随机分为治疗组和对照组。两组均采用常规治疗，治疗组在常规治疗的基础上静脉输注依达拉奉30mg，每日2次，共14d。采用“中国脑卒中病人临床神经功能缺损程度评分标准”对治疗后3d、7d、14d患者进行疗效评价。结果治疗3d开始起效，7d及14d治疗组神经功能缺损程度评分显著低于对照组（氏0．05）。秩和检验显示治疗组的疗效显著优于对照组（P〈0．05）。结论依达拉奉治疗急性脑梗死安全有效。
Objective To evaluate the efficacy and safety of edaravone for acute cerebral infarctions. Methods Eighty-two patients were divided into treatment group and control group randomly. Forty-one in treatment group received routine therapy and edaravone, and Forty-one in control group received routine therapy only. China Stroke Scale （CSS） was used to evaluate the recovery of neurological functions. Results Treatment began to exert its effect fi＇om the third day, and neurological function deficit scores of the treatment group at 7 and 14 d were evidently lower than those of the control group （P〈0.05）. The rank sum test indicated that the efficacy of the treatment group were obviously superior to that of the control group （P〈0.05）. Conclusion Edaravone was effective and safe for acute cerebral infarctions.
出处
《中华神经医学杂志》
CAS
CSCD
2008年第1期54-55,共2页
Chinese Journal of Neuromedicine
关键词
依达拉奉
自由基清除剂
脑梗死
Edaravone
Free radical scavenger
Cerebral infarction
